
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
IONS | NASDAQ | USD | Real-time | |
ISI | Frankfurt | EUR | Delayed | |
ISI | TradeGate | EUR | Delayed |
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Name | Age | Since | Title |
---|---|---|---|
Joseph Klein | 60 | 2005 | Independent Director |
Spencer Robert Berthelsen | 69 | 2002 | Independent Director |
Joseph Loscalzo | 70 | 2014 | Independent Chairman of the Board |
Joseph Harris Wender | 77 | 1994 | Lead Independent Director |
Michael R. Hayden | 71 | 2018 | Independent Director |
Allene Maria Diaz | 58 | 2021 | Independent Director |
Joan Elizabeth Herman | 68 | 2019 | Independent Director |
Brett P. Monia | 62 | 2012 | Founder, CEO & Director |
Michael J. Yang | 62 | 2023 | Independent Director |
B. Lynne Parshall | 71 | 1991 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review